Clinical Data, Inc. (NASDAQ: CLDA), a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as clinical diagnostics to improve patient care, today announced that it has received a letter from the U.S. Food and Drug Administration (FDA) regarding the regulation of genetic testing. The letter invited the Company to meet with the FDA to discuss the nature and appropriate regulatory status of the Company’s tests and, if any regulatory requirements apply, the least burdensome ways that the Company may fulfill them. Accordingly, Clinical Data plans to meet with the FDA in the near future.
